GlaxoSmithKline to limit payments it makes to US doctors to $150 000 a yearBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2315 (Published 30 October 2008) Cite this as: BMJ 2008;337:a2315
- Zosia Kmietowicz
GlaxoSmithKline is to limit the advisory payments and honorariums it offers to doctors in the United States to $150 000 (£96 000; €120 000) a doctor a year. The company has also said that it will publish the amount of money it offers to doctors “without exception,” although doctors’ names will not be published.
Andrew Witty, chief executive of the company, told the Financial Times, “It’s appropriate that we have a limit on what we pay. In the past, whatever has happened has happened, but in the future there will be strict adherence to these caps, which will be clearer to everybody” (23 Oct, p 22).
A spokeswoman for the company said that it had no plans to introduce a cap on payments …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial